1
|
Hofmann N, Lafarge X, Antica M, Ferry N, Girandon L, Gramignoli R, Jurga M, Kerdjoudj H, Navakauskiene R, Schiavi J, Shablii V, Nicolás FJ, Gindraux F. Expert Consideration on Regulatory Aspects for Perinatal Derivatives in Clinical Settings. Stem Cells Transl Med 2023; 12:258-265. [PMID: 37027834 PMCID: PMC10184691 DOI: 10.1093/stcltm/szad017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2023] [Accepted: 03/10/2023] [Indexed: 04/09/2023] Open
Abstract
Perinatal derivatives (PnD) are drawing growing interest among the scientific community as an unrestricted source of multipotent stem cells, secretome, and biological matrices. They are useful for the treatment of diseases that currently have limited or no effective therapeutic options, but they require the development of regenerative approaches. With this development, the question of regulation of donation, processing, and distribution has therefore become more important. Within the European Cooperation in Science and Technology (COST) community, we compiled a group of international experts on PnD technologies, who revised and compared existing EU national regulations. Notably, despite clear European directives, each EU Country has developed their own implementation and standard levels for cell- and tissue-based therapies. To enable extended applications of PnD treatments within the EU community and worldwide, harmonization is highly recommended. This paper aims to provide an overview of the various options available to introduce PnD into clinical practice. For this purpose, the different aspects resulting from (1) the type of PnD, (2) the amount of available data, (3) the degree of manipulation, and (4) the intended application and the process toward a possible commercialization will be presented. In the future, it will be important to find a balance between regulatory requirements and the best medical quality of the PnD product.
Collapse
Affiliation(s)
- Nicola Hofmann
- German Society for Tissue Transplantation (DGFG) gGmbH, Hannover, Germany
| | - Xavier Lafarge
- Etablissement Français du Sang Nouvelle-Aquitaine Laboratoire d'ingénierie tissulaire et cellulaire, Bordeaux, France
- INSERM U1211 « Maladies Rares: Génétique et Métabolisme, Bordeaux, France
| | | | - Nicolas Ferry
- INSERM, Department of health technology, Île-de-France, Paris, France
| | | | - Roberto Gramignoli
- Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm, Sweden
- Medicinsk Cancerdiagnostik, Karolinska University Hospital, Stockholm, Sweden
| | | | - Halima Kerdjoudj
- Université de Reims Champagne Ardenne, Odontology, EA4691-BIOS, Reims, France
| | - Ruta Navakauskiene
- Department of Molecular Cell Biology, Institute of Biochemistry, Life Sciences Center, Vilnius, Lithuania
| | - Jessica Schiavi
- CNRS, LRGP, Department of Biomolecules Bioprocess, University of Lorraine, Nancy, France
| | - Volodymyr Shablii
- Laboratory of Biosynthesis of Nucleic Acids, Institute of Molecular Biology and Genetics, Department of Functional Genomics, National Academy of Science, Kyiv, Ukraine
- Placenta Stem Cell Laboratory, Cryobank, Institute of Cell Therapy, Kyiv, Ukraine
| | - Francisco J Nicolás
- Lab. Regeneración, Oncología Molecular y TGFß. IMIB-Pascual Parrilla. El Palmar, Murcia, Spain
| | - Florelle Gindraux
- Service de Chirurgie Maxillo-Faciale, Stomatologie et Odontologie Hospitalière, CHU Besancon, Besancon, France
- Université de Franche-Comté, Laboratoire de Nanomédecine, Imagerie, Thérapeutique EA 4662 (LNIT), Besançon, France
| |
Collapse
|